Questcor Pharmaceuticals — Q3 2012 Earnings Presentation
10 slides from Questcor Pharmaceuticals's earnings presentation, Oct 25, 2012
Slide 1: Third Quarter 2012 Conference Call
Third Quarter 2012 Conference Call Exhibit 99.3 Third Quarter 2012 Conference Call NASDAQ: QCOR
Slide 2: Conference Call Logistics
2 • Today’s webcast, accompanying slide presentation and archived replay is available online at • Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 39696380 • By webcast: At Questcor's investor relations website: Conference Call Logistics
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 4: 3Q-12 Results
4 • 335 paid NS scripts • 1,291 paid MS scripts • 102 paid IS scripts • Financial results – 5,590 vials shipped, up 92% YOY – $140.3M in net sales, up 135% YOY – $0.91 GAAP EPS (diluted), up 160% YOY 3Q-12 Results • 335 paid NS scripts • 1,291 paid MS scripts • 102 paid IS scripts • Financial result
Slide 5: Growth in Shipped Vials
5 Growth in Shipped Vials 1,000 2,000 3,000 4,000 5,000 6,000 Q1-10 Q2-10 Q3-10 Q4-10 Q1-11 Q2-11 Q3-11 Q4-11 Q1-12 Q2-12 Q3-12 Shipped Vials Shipped Vials
Slide 6: Paid Rxs NS Scripts-Strong Continued Growth
6 Paid Rxs NS Scripts-Strong Continued Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo
Slide 7: MS Scripts-Record of Consistent Growth
7 Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely rel
Slide 8: The Emerging Science Behind Acthar
8 • Understanding the biological properties of Acthar – Specific biochemical pathways, cells, and tissues – Immunomodulation and anti-inflammatory effects • Further research related to on-label indications • Possible new indications to explore The Emerging Science Behind Acthar Preclinical and Clini
Slide 9: 3Q-12 Results
9 • 335 paid NS scripts • 1,291 paid MS scripts • 102 paid IS scripts • Financial results – 5,590 vials shipped, up 92% YOY – $140.3M in net sales, up 135% YOY – $0.91 GAAP EPS (diluted), up 160% YOY 3Q-12 Results • 335 paid NS scripts • 1,291 paid MS scripts • 102 paid IS scripts • Financial result
Slide 10: Third Quarter 2012 Conference Call
Third Quarter 2012 Conference Call Third Quarter 2012 Conference Call NASDAQ: QCOR
Questcor Pharmaceuticals — Q3 2012 Earnings Presentation on 6ix